According to a report by Reuters on September 25th, executives from Smoore International, Hangsen International Group, and Zinwi Biotech have stated that they are researching nicotine-like chemical substances that could serve as alternatives to nicotine in products such as e-cigarettes. However, the health effects of these chemicals may require "several years" of investigation.
Previously, a chemical substance called 6-methyl nicotine has been manufactured in the laboratory with a chemical structure similar to nicotine, and is already being used in some e-cigarettes in the United States. However, regulatory agencies and researchers warn that it may be more potent and addictive than nicotine itself.
E-cigarette-liquid manufacturers Hangsen International Group, Zinwi Biotech, and Smoore International all stated that more research is needed to determine the safety of these chemicals.
Eve Wang, Executive Director of Smoore International, said in an interview with Reuters on Wednesday (25th) that...
“Smoore will not act hastily.”
She stated that a small team at Smoore International is researching these chemical substances called nicotine analogues to understand how they work and their effects.
We should treat it like a drug, thoroughly understand its health impacts before commercializing it... I believe this will require many years of research.
The director of the Hengxin International Research Institute, Yu Kang, and the global communications manager of Zinwi Bio Technology, Haley Xu, stated that their companies are also researching such chemical substances.
Yu Kang stated at the 2024 Global Tobacco and Nicotine Forum (GTNF) held in Athens, Greece, that
We must be extremely careful and thoroughly evaluate whether and how to use them.
He said that Hengxin International is currently researching approximately 10 types of nicotine analogues, including 6-methyl nicotine.
Haley Xu stated that Zinwi Bio is also researching over 10 similar compounds and will ensure their safety before releasing any nicotine analog products.
We welcome news tips, article submissions, interview requests, or comments on this piece.
Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn
Notice
1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.
2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.
3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.
4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.
Copyright
This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.
For copyright-related inquiries, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.
We welcome any corrections or feedback. Please contact us at: info@2firsts.com
